Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists

Details for Australian Patent Application No. 2005210621 (hide)

Owner Yale University Biogen Idec MA Inc.

Inventors Relton, Jane K.; Strittmatter, Stephen M.; Engber, Thomas M.

Agent Cullen & Co

Pub. Number AU-B-2005210621

PCT Pub. Number WO2005/074972

Priority 60/540,798 30.01.04 US

Filing date 28 January 2005

Wipo publication date 18 August 2005

Acceptance publication date 1 October 2009

International Classifications

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

31 August 2006 PCT application entered the National Phase

  PCT publication WO2005/074972 Priority application(s): WO2005/074972

1 October 2009 Application Accepted

  Published as AU-B-2005210621

4 February 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005210623-Methods for treatment of complications of diabetes

2005210618-Compositions containing internally activated antioxidant